No retraction, correction or concern found when last checked on Nov 1, 2026.

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Rebecca P. Payne, Stephanie Longet, James A. Austin and 97 more

Cell · 2021 · CC BY

doi:10.1016/j.cell.2021.10.011

Abstract

Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6–14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4 + T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol.

References 47

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity · 2020
No notice
11.
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses · 2021
No notice
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection · 2021
No notice
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera · 2021
No notice
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials · 2021
Corrected
21.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera · 2021
No notice
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
Antibody evasion by the P.1 strain of SARS-CoV-2 · 2021
No notice
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination · 2021
No notice
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
Evidence for antibody as a protective correlate for COVID-19 vaccines · 2021
No notice
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum · 2021
No notice
34.
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection · 2021
No notice
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
37.
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern · 2021
No notice
38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
39.
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study · 2022
No notice
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

All 47 references

Cited by papers we hold 9

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease · 2023
No notice
N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting · 2023
No notice
Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine · 2022
Not checked
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines · 2022
No notice
Extended interval BNT162b2 vaccination enhances peak antibody generation · 2022
No notice
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway · 2022
Corrected
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines · 2022
No notice
SARS-CoV-2 Variants, Vaccines, and Host Immunity · 2022
No notice
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines · 2022
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.